早期应用阿托伐他汀对病毒性心肌炎患者的免疫调控研究

Immune Regulation of Atorvastatin on Patients with Early Stage of Viral Myocarditis

目的:研究应用阿托伐他汀治疗早期病毒性心肌炎患者对T淋巴细胞亚群及血清炎症因子的影响。方法:将符合成人急性病毒性心肌炎患者60例随机分为治疗组(A组,30例)、对照组(B组,30例),两组患者均给予常规治疗。A组在常规治疗基础上给予阿托伐他汀,B组只给予常规治疗,服药持续时间为四周。结果:两组治疗前T淋巴细胞亚群比较无显著性差异,TNF-α及IL-10浓度比较亦无显著差异,两组治疗后比较,CD3+、CD4+、CD8+升高,CD4+/CD8+比值变小,TNF-α浓度降低,IL-10浓度升高,治疗前后有显著性差异(P<0.05)。治疗组与对照组治疗后比较,差异非常显著(P<0.01)。结论:阿托伐他汀能够下调炎症因子水平和上调抗炎因子水平从而改变炎症因子网络平衡,对急性病毒性心肌炎患者具有免疫调节作用。

Objective： To investigate the effect of early intervention with atorvastatin on T-lymphocyte subsets and serum inflammatory cytokines in patients with acute viral myocarditis （AVMC）. Methods： 60 acute viral myocarditis patients were randomly divided into treatment group （A, 30cases） and control group （B,30cases）. Conventional medical therapy was given to two groups and group A were treated with atorvastatin. The therepeutic course for both groups was 4 weeks. Results： There was no statistical difference for T-lymphocyte subsets and concentration of TNF-α and IL-10 between two groups before treatment. After treatment, the CD3＋, CD4＋, CD8＋ increased, the ratio of CD4＋/CD8＋decreased. The TNF-α decreased, while the serum concentration of IL-10 increased, and there was significant differences between before and after treatment （P〈0.05）; There was significant differences between treatment group and control group （P〈0.01）; Conclusions： Atorvastatin can alter the internal balance of inflammatory factor by cutting down the levels of inflammatory factors and raising anti-inflammatory factors, which had immune adjustment function in acute viral myocarditis patients.